Microarrays Aim for Center Stage

Accepted in discovery, microarrays are paving the way for biomarker development and eventually, molecular diagnostics.

VCs and entrepreneurs first became interested in microarray technologies for genomic applications more than a decade ago, as a method of sorting overwhelming amounts of information systematically, quickly and affordably. Silicon chips gleaned from the computer world formed the foundation of the early microarrays. Each chip provided dozens and later tens of thousands of data points, depending on the number of analytes they could hold. Their capabilities grew as feature size shrank in accordance with Moore's Law, which predicts that the number of microcomponents that can fit on a semiconductor chip for the same cost will double every 18 months. At the same time, developers and users began to apply significant bioinformatics muscle to power the algorithms used to interpret the resulting data.

Genomic tool companies provided systems, including chips, detection technologies and reagents. Competition was fierce and based on price, ease of...

Welcome to Scrip

Create an account to read this article

More from R&D

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

More from Scrip

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Rocket Comes Back To Earth With Restructuring Plan

 

The biotech will lay off nearly one-third of its workforce and focus on its cardiovascular gene therapy programs.